Adverum Biotech (ADVM.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov17

Mizuho Securities analyst maintains 'buy' rating on Adverum Biotechnologies

11:21

Nov13

Adverum Biotech released FY2025 Q3 earnings on November 12, 2025, EST: Actual Revenue USD 0 (Forecast USD 0), Actual EPS USD -2.03 (Forecast USD -1.755)

04:00

Adverum Biotech released FY2025 9 Months Earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -6.6158

04:00

Oct29

Suvannavejh's Performance in Recommending Healthcare Stocks

11:51

Oct25

Gataulin Downgrades Adverum Biotechnologies Rating

00:16

Oct24

Eli Lilly Acquires Adverum Biotechnologies to Boost Gene Therapy

12:31

Schedules & Filings

Schedules

Filings

Nov12

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -47.65 M, EPS -2.0288

Aug12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -49.19 M, EPS -2.3413

May14

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -47.02 M, EPS -2.2456

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change